Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Quentin M. Anstee, Laurent Castéra, Rohit Loomba
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1362-1378
Open Access | Times Cited: 149

Showing 1-25 of 149 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 287
Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 11, pp. 708-722
Closed Access | Times Cited: 138
Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
Daniel Q. Huang, Laura Wilson, Cynthia Behling, et al.
Gastroenterology (2023) Vol. 165, Iss. 2, pp. 463-472.e5
Open Access | Times Cited: 86
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Monica A. Tincopa, Rohit Loomba
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 660-670
Closed Access | Times Cited: 84
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
Laurent Castéra, Cédric Laouénan, Anaı̈s Vallet-Pichard, et al.
Diabetes Care (2023) Vol. 46, Iss. 7, pp. 1354-1362
Open Access | Times Cited: 74
Noninvasive Assessment of Liver Fibrosis in NAFLD
Arun J. Sanyal, Laurent Castéra, Vincent Wai–Sun Wong
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2026-2039
Closed Access | Times Cited: 73
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1482-1490
Open Access | Times Cited: 72
A global research priority agenda to advance public health responses to fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 618-634
Open Access | Times Cited: 71
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
Daniel Q. Huang, Nabil Noureddin, Veeral Ajmera, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 829-836
Open Access | Times Cited: 71
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 62
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 49
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease
David Martí‐Aguado, José Luís Calleja, Eduardo Vilar‐Gómez, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 6, pp. 930-940
Closed Access | Times Cited: 31
Ammonia detection: A pathway towards potential point-of-care diagnostics
Ronil J. Rath, Jack Herrington, Muhammad Adeel, et al.
Biosensors and Bioelectronics (2024) Vol. 251, pp. 116100-116100
Open Access | Times Cited: 22
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 20
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Maja Thiele, Ida Falk Villesen, Lili Niu, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 345-359
Open Access | Times Cited: 16
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 16
Quantification of Vascular Remodeling and Sinusoidal Capillarization to Assess Liver Fibrosis with Photoacoustic Imaging
Wenya Li, Jing Lv, Honghui Li, et al.
Radiology (2025) Vol. 314, Iss. 1
Closed Access | Times Cited: 3
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Hung‐Wei Wang, Yi Zeng, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association (2025)
Open Access | Times Cited: 3
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai–Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 3
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
Rohit Loomba, Daniel Q. Huang, Arun J. Sanyal, et al.
Gut (2022) Vol. 72, Iss. 3, pp. 581-589
Open Access | Times Cited: 62
Risk stratification and early detection biomarkers for precision HCC screening
Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, et al.
Hepatology (2022), pp. n/a-n/a
Open Access | Times Cited: 60
Diabetes and cirrhosis: Current concepts on diagnosis and management
Laurent Castéra, Kenneth Cusi
Hepatology (2023) Vol. 77, Iss. 6, pp. 2128-2146
Closed Access | Times Cited: 38
A global action agenda for turning the tide on fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, et al.
Hepatology (2023) Vol. 79, Iss. 2, pp. 502-523
Open Access | Times Cited: 33
Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality
Stefano Ballestri, Alessandro Mantovani, Maria Di Girolamo, et al.
Metabolism and Target Organ Damage (2023) Vol. 3, Iss. 1, pp. 1-1
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top